Biotech marketing builds credibility with the audiences that decide a company’s future — investors, key opinion leaders, potential pharma partners, and scientific recruits — rather than patients. Most biotech companies are marketing a science and a team before there is an approved product to promote, which makes the discipline closer to investor relations and scientific communication than to consumer healthcare marketing.
That distinction explains why generalist agencies struggle here. This guide covers who you are actually marketing to, how strategy shifts by company stage, which channels produce partnering conversations, and what FDA and FTC rules allow you to say.
What Is Biotech Marketing, and How Is It Different From Pharma?
Pharmaceutical marketing usually promotes an approved product to prescribers or patients under FDA and OPDP rules. Biotech marketing typically happens earlier: there is a pipeline, a mechanism, and a team, but often no approved product at all.
The practical differences:
| Biotech marketing | Pharmaceutical marketing | |
|---|---|---|
| Primary audience | Investors, KOLs, BD teams, partners, recruits | Prescribers, payers, patients |
| What is being sold | The science, the pipeline, the company | An approved product |
| Core goal | Funding, partnering, talent, credibility | Prescriptions, formulary access, adherence |
| Main constraint | Pre-approval promotion limits, securities-adjacent care | OPDP fair balance, ISI requirements |
| Success metric | Qualified partnering and investor conversations | Script volume, share, access |
Both sit inside the same regulated universe, and companies often need both as they approach commercialization. If you are closer to launch, our pharmaceutical marketing agency work covers the HCP and patient side of that transition.
Who You Are Actually Marketing To
Getting the audience wrong is the most common and most expensive biotech marketing mistake. There are four real audiences, and they read completely differently.
Investors and analysts. They need the significance made plain: what problem, how big, why this mechanism, what milestone comes next, and what de-risks it. They are usually not specialists in your specific target, so jargon without translation reads as evasion rather than rigor.
Key opinion leaders and the scientific community. The opposite problem. This audience scrutinizes mechanism, endpoints, and data quality. Oversimplify and you lose credibility permanently. KOL engagement is earned with real scientific substance — publications, congress presence, and data — not with marketing language.
Business development and potential partners. Pharma BD teams are scanning for assets that fit a therapeutic area strategy. They need your pipeline, stage, differentiation, and IP position findable and legible within a few minutes.
Recruits. Scientific talent is a constraint on most biotech companies, and candidates research a company’s credibility and momentum before replying. Your public presence is a recruiting asset whether or not you treat it as one.
Not sure which audience your current messaging actually serves? Request a biotech marketing review and we will map your site, pipeline story, and investor materials against the four audiences above.
Biotech Marketing Strategy by Company Stage
The right strategy changes with where you are. Spending like a commercial-stage company while you are preclinical wastes capital; spending like a preclinical company while approaching launch loses the market.
| Stage | Primary goal | Where budget goes |
|---|---|---|
| Preclinical / seed | Scientific credibility, early investor interest | Corporate identity, a credible website, founder and scientific visibility |
| Clinical (Ph I-II) | Sustained investor confidence, KOL relationships | Pipeline and data communication, congress presence, search visibility for named entities |
| Partnering / pre-IPO | Attract BD and institutional investors | Equity story, analyst-ready materials, brand consistency, targeted outreach |
| Commercial-stage | Launch readiness, market shaping | Disease-state education, HCP channels, full regulatory review workflows |
A common failure is treating the corporate website as a brochure that gets rebuilt once at Series B. In practice it is the single asset every one of the four audiences checks, usually before any conversation happens.
The Channels That Actually Work in Biotech
Biotech has a small, high-value audience, so channel selection looks nothing like consumer healthcare.
Search and AI answer engines. When an analyst, partner, or candidate searches your company, your target, or your mechanism, what surfaces shapes the first impression. That now includes AI assistants summarizing your company from whatever they can find. Making your science accurately machine-readable — clean site structure, clear entity naming, schema markup — is increasingly part of the job.
The corporate and pipeline website. Pipeline pages, publications, team credentials, and a clear mechanism explanation do more partnering work than any campaign. This is where scientific credibility is either established or lost.
Scientific congresses and publications. Still the center of gravity for KOL credibility. Marketing’s role is amplification and translation, not substitution.
LinkedIn and targeted outreach. Where BD professionals, venture investors, and scientific talent actually spend time. Account-based approaches beat broad campaigns when the total addressable audience is a few hundred people.
Investor and media relations. Milestone communication, data readouts, and financing news, coordinated so the story compounds rather than fragmenting.
Broad paid advertising is rarely the answer. When the entire relevant audience for a partnering conversation could fit in one room, precision beats reach.
What You Can and Cannot Say
This is where biotech marketing gets companies into trouble, and where specialist help pays for itself.
Pre-approval promotion is restricted. You cannot promote an investigational product as safe or effective for its intended use before approval. Scientific exchange and disease-state education are permitted; promotional claims about an unapproved product are not.
Claims must be truthful, balanced, and substantiated. The FTC requires substantiation for advertising claims, and the FDA holds product communications to fair-balance standards. “Breakthrough,” “first-in-class,” and efficacy implications all need to hold up.
Forward-looking statements carry separate risk. For public or soon-to-be-public companies, marketing language can create securities exposure. Marketing, legal, and IR need to review the same materials.
The practical rule we use: describe the science and the company confidently, describe the product cautiously, and never let a marketing document make a claim that the data cannot support. A specialist biotech marketing agency should be building messaging inside these constraints from the first draft, not sending it to legal to be rescued.
How Biotech Marketing Should Be Measured
Impressions are close to meaningless here. Meaningful measures are:
- Qualified partnering or BD conversations initiated
- Inbound investor interest and quality of inbound
- Analyst and media coverage accuracy
- Candidate quality and time-to-hire for scientific roles
- Accuracy of how AI assistants and search describe your company
Because the buying population is tiny and cycles are long, attribution is more qualitative than in consumer healthcare. That is normal. The mistake is importing consumer KPIs and concluding the program failed because a landing page did not convert at 4%.
For companies that also need a broader commercial plan, our healthcare marketing consulting engagements connect the stage strategy to an executable roadmap, and our medical device marketing practice covers the device and diagnostics side of life sciences.
Frequently Asked Questions
What does a biotech marketing agency do?
A biotech marketing agency builds credibility with investors, key opinion leaders, potential partners, and recruits rather than patients. It handles scientific branding, corporate and pipeline websites, search and AI visibility, congress and investor materials, and targeted outreach, all inside FDA and FTC substantiation rules.
How is biotech marketing different from pharmaceutical marketing?
Pharmaceutical marketing promotes an approved product to prescribers or patients. Biotech marketing usually sells a science and a company before there is an approved product, so it centers on credibility, the pipeline story, and the equity narrative rather than product promotion.
Can you advertise a drug that is not FDA approved yet?
No. Promoting an investigational product as safe or effective for its intended use before approval is not permitted. Scientific exchange, disease-state education, and factual corporate and pipeline communication are allowed, which is why biotech messaging focuses on the company and the science.
How much should a biotech company spend on marketing?
It varies far more by stage than by revenue. Preclinical companies often need a defined branding and website project rather than a retainer, while companies approaching partnering or launch invest continuously in investor visibility and launch readiness. Cost per qualified partnering conversation is the sensible measure, not cost per click.
Does biotech marketing include investor relations?
They overlap and must be coordinated, but they are not identical. Marketing shapes the narrative, brand, and visibility; investor relations manages disclosure and the investor relationship. For public companies the two functions need to review the same language before it goes out.
How do biotech companies get found by pharma partners?
Mostly through scientific visibility, congress presence, publications, and being easy to evaluate online. BD teams scan for assets that fit a therapeutic strategy, so a pipeline page that clearly states stage, mechanism, differentiation, and IP position does more partnering work than outbound campaigns.
Build a Biotech Story That Survives Due Diligence
Most biotech companies do not have a visibility problem so much as a translation problem: the science is strong, and the way it is presented does not land with the audience holding the decision.
We build the brand, the website, and the visibility program around the four audiences that matter — and inside the regulatory limits that apply before approval.
Request a biotech marketing review → or email info@medibrandly.com to see what we would change first.